Document is current

Article History

Received: 28 December 2020

Accepted: 13 October 2021

First Online: 29 October 2021

Declarations

:

: The study complied with Good Clinical Practice standards and the principles of the latest version of the Helsinki Declaration (Brazil, 2013) and was approved by the Parc Taulí Ethics Committee. Confidentiality and anonymity were guaranteed in accordance with the Spanish Law 15/1999 on personal data protection.The surveys contained an initial written explanation of the purpose of the study and an invitation to anonymously participate if the patient consent to participate.

: Not applicable.

: Xavier Calvet has served as speaker, consultant and advisory member for, or has received research funding from MSD, Abbvie, Pfizer, Kern Pharma, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma, Otsuka Pharmaceutical and Vifor Pharma. Francesc Casellas has served as speaker, consultant and advisory member for, or has received research funding from Merck Sharp & Dohme, Abbvie, Pfizer, Takeda, Janssen, Ferring, Faes Farma, Shire Pharmaceuticals, Tillotts Pharma and Ferrer. Daniel Carpio has served as speaker, consultant and advisory member for, or has received research funding from Merck Sharp & Dohme, Abbvie, Kern Pharma, Takeda, Janssen, Ferring, Shire Pharmaceuticals, Tillotts Pharma, Dr Falk Pharma, Gebro Pharma. Berta Juliá is an employee of Merck Sharp & Dohme, Spain. Maribel Vera has served as speaker, consultant and advisory member and has received funding from MSD, Abbvie, Pfizer, Ferring, Shire Pharmaceuticals, Takeda and Jannsen.